SYNGENE Q2 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹910.1 Cr
verified against source
Revenue YoY
18.5%
reported change
EBITDA
₹254 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene delivered INR 910 crore in Q2 revenue (18.5% YoY, 15% CC), with EBITDA of INR 254 crore (17.4% growth) and PAT of INR 122 crore (20% growth). The quarter was driven by development and manufacturing services, where the Zoetis biologics contract reached a $50M annual run-rate. However, discovery services faced temporary headwinds from U.S. biotech funding normalization, prompting downward revision of full-year revenue guidance from high-teens to mid-teens constant currency growth. Management maintained FY24 EBITDA margin guidance at ~30% and expects H2 margins to exceed H1's 28%. The Stelis Biopharma facility acquisition is on track to close this quarter, and the company purchased 17 acres in Hyderabad's Genome Valley for future expansion. The near-term slowdown in small U.S. biotechs (estimated 15% of revenue) is viewed as temporary, with funding stabilizing at pre-pandemic levels. CapEx guidance reduced from $85M to $80M for FY24.
Colored figures show movement against the previous available record.
Guidance to track
- Full-year revenue guidance adjusted from high-teens to mid-teens constant currency growth due to near-term slowdown in U.S. biotech demand. Reported growth will be higher due to currency tailwinds. Strong Q4 recovery expected.
- Full-year EBITDA margin guidance maintained at approximately 30%. H1 margin was 28%, implying H2 margins will be higher than H1 to achieve full-year target.
- CapEx guidance revised down from $85M to $80M; $30M executed in H1, another $20M already committed. Over 50% allocated to research business, ~$5-7M for Stelis facility upgrades, remainder to small molecule CDMO and enterprise initiatives.
- Acquisition of multimodal biopharma facility from Stelis Biopharma is progressing through closing conditions. Expected to close in the current quarter. Pre-operational expenses will be capitalized post-acquisition.
Risks flagged
- Temporary softening in U.S.-based biotech segment as companies adjust to higher interest rate environment. Management expects this to normalize in 1-2 quarters as funding stabilizes at pre-pandemic levels, but Q3 will see most of the impact with recovery in Q4.
- Raw material costs increased 34% YoY due to shift toward development and manufacturing services which have inherently higher material content. Raw materials as percentage of revenue expected to stabilize at 27-28% for full year vs 29% in Q2.
- Analyst asked about acquisition timeline and potential cost overruns. Management deflected with 'checklist, not timetable' response. No specific commercial update provided on new client pipeline or facility ramp-up post-acquisition.
- Analyst asked whether Inflation Reduction Act would shift investment from small to large molecules, potentially impacting Syngene's small molecule business. CEO dismissed as '10-year discovery cycle' issue with no immediate impact but acknowledged it was too early to see any effects.
Key quotes
- The really easy answer to your question is no, we've seen no impact whatsoever [from IRA], but I'm not sure that's particularly informative. I would expect this to play out over the next five, 10, 20 years.
- We're a broad-based business. We've got 450+ active clients. They cover from, I think, the very largest pharmaceutical company in the world to the smallest, newest biotech startup. So we span that whole range.
- If capital is harder to get and more expensive, you may well only get a smaller amount of investment, in which case you have to work hard to make it go further. And if you can get equivalent science, equivalent service, world-class regulatory compliance for a lower dollar amount, then yeah, it sharpens the value proposition we have.
Research modules